Triazole derivatives useful as Axl inhibitors

1. A method of treating a disease or condition associated with Axl catalytic activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (Ia) or formula (Ib):

wherein, independently at each occurrence:

A is —C(O)— or —C(S)—;

R 1 is aryl substituted with at least one of —R 8 —OR 10 or —R 8 —O—R 9 —CN, where each R 8 is a direct bond and R 10 is selected from the group consisting of optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl and optionally substituted aralkyl, and optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, alkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and alkoxy;

R 2 , R 4 and R 5 are each independently hydrogen, alkyl, aryl, aralkyl, —C(O)R 10 or —C(O)N(R 6 )R 7 ;

R 3 is one of the following:

a) aryl optionally substituted with one or more substituents selected from the group consisting of alkyl, halo; haloalkyl, nitro, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —R 8 —OR 10 , —R 8 —C(O)OR 10 , —R 8 —OC(O)R 10 , —R 8 —O—R 9 —C(O)OR 10 , —R 8 —O—R 9 —C(O)N(R 6 )R 7 , —S(O) p R 6 (where p is 0, 1 or 2), —S(O) t N(R 6 )R 7 (where t is 1 or 2), —R 8 —N(R 6 )R 7 , —R 8 —N(R 6 )C(O)R 10 , —R 8 —N(R 6 )C(O)OR 10 and —R 8 —CN; or

b) optionally substituted heteroaryl;

R 6 and R 7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R 9 —CN, —R 9 —NO 2 , —R 9 —N(R 10 ) 2 , —R 9 —C(O)OR 10 and —R 9 —C(O)N(R 10 ) 2 ;

optionally, R 6 and R 7 , together with the nitrogen to which they are attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl;

each R 8 present in a R 3 substituent is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;

each R 9 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; and

R 10 present in the R 2 , R 4 and R 5 substituents and each R 10 present in a R 3 substituent, a R 6 substituent or a R 7 substituent is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl;

as an isolated stereoisomer or tautomer thereof or mixtures thereof,

or a pharmaceutically acceptable salt or N-oxide thereof.

2. The method of claim 1 wherein the disease or condition associated with Axl catalytic activity is selected from the group consisting of endometriosis, rheumatoid arthritis, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, osteoarthritis, cataracts, vascular diseases selected from the group consisting of restenosis, atherosclerosis, and thrombosis, vascular injury, kidney diseases selected from the group consisting of glomerulonephritis, diabetic nephropathy and renal transplant rejection, solid tumors selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, prostate carcinoma, gastric cancer and uveal melanoma, and liquid tumors selected from the group consisting of myeloid leukemia and lymphoma.

3. The method of claim 2 wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease selected from the group consisting of restenosis, atherosclerosis and thrombosis, and vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease selected from the group consisting of glomerulonephritis, diabetic nephropathy and renal transplant rejection, osteoarthritis, and cataracts.

4. The method of claim 2 , wherein the disease or condition is solid tumors selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, prostate carcinoma, gastric cancer and uveal melanoma.

5. The method of claim 2 , wherein the disease or condition is liquid tumors selected from the group consisting of leukemia and lymphoma.

6. The method of claim 2 wherein the disease or condition is endometriosis.